Pharma IQ Members

Adverse Drug Reaction (ADR)

Adverse Drug Reaction (ADR) is an expression that describes harm associated with the use of given medications at a normal dose. Adverse events can range from mild to severe. Serious adverse drug reactions are those that can cause disability, are life-threatening, result in hospitalization or death, or are birth defects.

Pharma IQ

The Asia Pacific region is fast becoming the growth center of the worldwide pharmaceuticals market. By 2015, these markets are projected to account for almost a third of the total pharmaceutical sales worldwide. 

But with this increased...

Contributor: Pharma IQ
05/08/2012 08:00:00 PM EDT
Dr Nasser Al-Qahtani
Dr. Nasser Al-Qahtani, Head, Adverse Drug Reactions Evaluations Department, Saudi FDA, joins Pharma IQ to discuss the Saudi FDA’s pharmacovigilance system and what new guidelines he predicts will be areas for discussion amongst pharma/biodiversity...
Contributor: Dr Nasser Al-Qahtani
02/22/2012 07:00:00 PM EST
Andrea Charles

In this interview Dr. Nasser Al-Qahtani, Head, Adverse Drug Reactions Evaluation Department Saudi FDA speaks to Andrea Charles from Pharma IQ, about the Saudi FDA pharmacovigilance system and what new guidelines he predicts will be areas for...

Contributor: Andrea Charles
12/12/2011 07:00:00 PM EST
Marc Descamps

Marc Descamps, Professor in Solid State Physics at Université Lille and Lead of the European ID Network for Improved Drug Efficacy and Availability, joins Pharma IQ to discuss the use of amorphous pharmaceutical materials to improve necessary...

Contributor: Marc Descamps
08/18/2011 08:00:00 PM EDT
Elie Magdalani

Pharmacology is the study of the effects of drugs. The other interesting branch known as the “clinical pharmacology” is interested in the effects of drugs in humans by which therapy is individualised according to the needs of each patient (based...

Contributor: Elie Magdalani
07/03/2011 08:00:00 PM EDT
Pharma IQ

Many companies in the pharmaceutical industry have provisions in place to deal with pharmacovigilance and other so-called late phase issues, as they realise the important role they can play in boosting the market penetration of products and –...

Contributor: Pharma IQ
05/18/2011 08:00:00 PM EDT
Elie Magdalani

Reported adverse events are an important tool for implementing a risk management program. An important contributing factor in the evolved AEs the condition of chronically ill patients taking a drug daily over the course of many years. Another...

Contributor: Elie Magdalani
05/05/2011 08:00:00 PM EDT
Pharma IQ

By the end of 2011 China's pharmaceutical market will be the third largest in the world, contributing more than $40 billion (£25 billion) in annual sales by 2013, according to analysis from IMS Health. India's pharmaceutical market will be...

Contributor: Pharma IQ
03/22/2011 08:00:00 PM EDT
Andrea Charles

Dr. Viraj Suvarna, Medical Director and Head of Medical Affairs at Boehringer Ingelheim, joins Andrea Charles from Pharma IQ to discuss the importance of training and re-training field operatives to report adverse drug events (ADEs) and how...

Contributor: Andrea Charles
03/22/2011 08:00:00 PM EDT
Elie Magdalani

“To undergo treatment you have to be very healthy, because apart from your sickness you have to withstand the medicine”. Molière (French Dramatist, 1622-1673)Although Molière was not a health care professional, but he understood very well that...

Contributor: Elie Magdalani
12/16/2010 07:00:00 PM EST
The Process of Drug Development: Time to Market

The term Drug Development covers a wide range of activities, from clinical trials to the creation of new compounds, all of which help drive a particular product to market. In its entirety, the process can take more than a decade, and cost...

Contributor: Pharma IQ
11/09/2010 07:00:00 PM EST
T. E. Gopala Krishna Murthy

Multiparticulates or multiple unit dosage forms are the discrete, small, repetitive units of drug particles which may or may not possess similar drug release pattern.  They can be tailored for pulsatile, controlled and or delayed, targeted drug...

Contributor: T. E. Gopala Krishna Murthy
09/27/2010 08:00:00 PM EDT
Bryan Camoens

Robert Lim, Head of Haematology and Oncology, for the National University Cancer Institute, speaks exclusively to Bryan Camoens from Pharma IQ, on the fundamental difference between pharmacodiligence and pharmacovigilance. Pharma IQ: What are...

Contributor: Bryan Camoens
08/11/2010 08:00:00 PM EDT
Pharma IQ

The application of nanobiotechnology has far ranging uses within a number of sectors of the life sciences industry, including drug discovery, formulation, clinical assessment, drug delivery and monitoring. A benchmark report on nanotechnology...

Contributor: Pharma IQ
08/11/2010 08:00:00 PM EDT
Pharmacovigilance in Asia: Will China One Day Take the Lead?

Jean Christophe Delumeau, Head of Pharmacovigilance Asia-Pacific for Bayer Healthcare Global R&D Centre, speaks exclusively to Bryan Camoens from Pharma IQ, on the evolution of Pharmacovigilance over the next decade.Pharma IQ:  What are the...

Contributor: Bryan Camoens
07/29/2010 08:00:00 PM EDT